Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- FRX.TO
- Price
- 7.08
- Stock movement down
- -0.50 (-6.60%)
- Company name
- Fennec Pharmaceuticals Inc
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 194.22M
- Ent value
- 217.99M
- Price/Sales
- 3.94
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 29.28
- PEG
- -
- EPS growth
- -52.61%
- 1 year return
- -48.58%
- 3 year return
- -73.58%
- 5 year return
- -56.41%
- 10 year return
- -26.53%
Last updated: 2025-04-18
DIVIDENDS
FRX.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | 8.23 |
| Price to FCF | 8.23 |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.94 |
| Price to Book | - |
| EV to Sales | 4.42 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 27.43M |
| EPS (TTM) | -0.04 |
| FCF per share (TTM) | 0.86 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 49.35M |
| Gross profit (TTM) | 46.15M |
| Operating income (TTM) | 1.68M |
| Net income (TTM) | -1.13M |
| EPS (TTM) | -0.04 |
| EPS (1y forward) | 0.24 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 93.52% |
| Operating margin (TTM) | 3.41% |
| Profit margin (TTM) | -2.30% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 40.32M |
| Net receivables | 12.91M |
| Total current assets | 57.97M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 58.92M |
| Accounts payable | 3.87M |
| Short/Current long term debt | 32.10M |
| Total current liabilities | 7.43M |
| Total liabilities | 64.09M |
| Shareholder's equity | -5.17M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 23.59M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 23.59M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -1.92% |
| Return on Invested Capital | 21.94% |
| Cash Return on Invested Capital | -456.89% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 7.08 |
| Daily high | 7.08 |
| Daily low | 7.08 |
| Daily Volume | 0K |
| All-time high | 5643.00 |
| 1y analyst estimate | 93.57 |
| Beta | 0.27 |
| EPS (TTM) | -0.04 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| FRX.TO | S&P500 | |
| Current price drop from All-time high | -99.87% | -14.12% |
| Highest price drop | -99.90% | -56.47% |
| Date of highest drop | 15 Nov 2024 | 9 Mar 2009 |
| Avg drop from high | -86.11% | -11.07% |
| Avg time to new high | 861 days | 12 days |
| Max time to new high | 4946 days | 1805 days |
COMPANY DETAILS
Marketcap
194.22M
Marketcap category
Small-cap
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Employees
29
Website
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
We feel now is a pretty good time to analyse Fennec Pharmaceuticals Inc.'s ( NASDAQ:FENC ) business as it appears the...
April 6, 2025
Fennec Pharmaceuticals Inc (FENC) reports a 40% revenue increase and successful PEDMARK launches in Europe, while navigating competitive challenges and operational expenses.
March 11, 2025
Q4 2024 Fennec Pharmaceuticals Inc Earnings Call
March 11, 2025
Fennec Pharmaceuticals' fourth-quarter Pedmark revenue of US$7.9 million beat Wedbush's US$7.6 milli
March 10, 2025
Investing in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago would have delivered you a 38% gain
The main point of investing for the long term is to make money. But more than that, you probably want to see it rise...
March 10, 2025
~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Mill...
March 10, 2025
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Com...
March 6, 2025
~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to <18 Years of Age with...
February 7, 2025
~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and yo...
December 20, 2024
~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million Shares ...
December 19, 2024
Next page